Lymph Node Activation by PET/CT Following Vaccination With Licensed Vaccines for Human Papillomaviruses
BACKGROUND: While PET using F-FDG is most commonly used for imaging malignant tumors, vaccination is known to cause transient inflammation of lymph nodes inducing positive findings on F-FDG PET scans. The pattern, magnitude, and duration of lymph node activation following vaccination have not been clearly defined. Furthermore, the addition of adjuvants to vaccines can further enhance the immune response. The presented study was designed to define lymph node activation following administration of the Food and Drug Administration-licensed human papillomavirus vaccines, Cervarix and Gardasil, which contain similar antigens with different adjuvants.
METHODS: Twenty-seven women aged 18 to 25 years were randomized to receive either Cervarix or Gardasil in the clinical trial VRC 900. Fifteen subjects participated in the PET/CT portion of the trial and received scans of lymph node activation at prevaccination and "1 week" (8-14 days) and "1 month" (23-36 days) after the first or third vaccination.
RESULTS: PET/CT scans revealed that all vaccine recipients had ipsilateral axillary lymph node activity. Three of 4 Cervarix recipients also showed contralateral lymph node activity 1 month after the first vaccination. For both Cervarix and Gardasil, the SUV activity resolved over time, with activity extended up to day 37 after the first and third vaccinations.
CONCLUSIONS: Following intramuscular vaccination, there were no major differences between duration of uptake and intensity of SUV between Cervarix and Gardasil recipients in ipsilateral axillary lymph nodes. Contralateral node activation was detected up to 1 month after the first vaccination in Cervarix recipients only, possibly reflecting differences in vaccine adjuvant formulation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Clinical nuclear medicine - 42(2017), 5 vom: 20. Mai, Seite 329-334 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Coates, Emily E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 |
|---|
| Anmerkungen: |
Date Completed 22.05.2017 Date Revised 03.01.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1097/RLU.0000000000001603 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM269787062 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM269787062 | ||
| 003 | DE-627 | ||
| 005 | 20231224225235.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/RLU.0000000000001603 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0899.xml |
| 035 | |a (DE-627)NLM269787062 | ||
| 035 | |a (NLM)28288041 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Coates, Emily E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Lymph Node Activation by PET/CT Following Vaccination With Licensed Vaccines for Human Papillomaviruses |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.05.2017 | ||
| 500 | |a Date Revised 03.01.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: While PET using F-FDG is most commonly used for imaging malignant tumors, vaccination is known to cause transient inflammation of lymph nodes inducing positive findings on F-FDG PET scans. The pattern, magnitude, and duration of lymph node activation following vaccination have not been clearly defined. Furthermore, the addition of adjuvants to vaccines can further enhance the immune response. The presented study was designed to define lymph node activation following administration of the Food and Drug Administration-licensed human papillomavirus vaccines, Cervarix and Gardasil, which contain similar antigens with different adjuvants | ||
| 520 | |a METHODS: Twenty-seven women aged 18 to 25 years were randomized to receive either Cervarix or Gardasil in the clinical trial VRC 900. Fifteen subjects participated in the PET/CT portion of the trial and received scans of lymph node activation at prevaccination and "1 week" (8-14 days) and "1 month" (23-36 days) after the first or third vaccination | ||
| 520 | |a RESULTS: PET/CT scans revealed that all vaccine recipients had ipsilateral axillary lymph node activity. Three of 4 Cervarix recipients also showed contralateral lymph node activity 1 month after the first vaccination. For both Cervarix and Gardasil, the SUV activity resolved over time, with activity extended up to day 37 after the first and third vaccinations | ||
| 520 | |a CONCLUSIONS: Following intramuscular vaccination, there were no major differences between duration of uptake and intensity of SUV between Cervarix and Gardasil recipients in ipsilateral axillary lymph nodes. Contralateral node activation was detected up to 1 month after the first vaccination in Cervarix recipients only, possibly reflecting differences in vaccine adjuvant formulation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 7 | |a Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 |2 NLM | |
| 650 | 7 | |a Papillomavirus Vaccines |2 NLM | |
| 650 | 7 | |a human papillomavirus vaccine, L1 type 16, 18 |2 NLM | |
| 700 | 1 | |a Costner, Pamela J |e verfasserin |4 aut | |
| 700 | 1 | |a Nason, Martha C |e verfasserin |4 aut | |
| 700 | 1 | |a Herrin, Douglas M |e verfasserin |4 aut | |
| 700 | 1 | |a Conant, Shielah |e verfasserin |4 aut | |
| 700 | 1 | |a Herscovitch, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Sarwar, Uzma N |e verfasserin |4 aut | |
| 700 | 1 | |a Holman, Lasonji |e verfasserin |4 aut | |
| 700 | 1 | |a Mitchell, Jillian |e verfasserin |4 aut | |
| 700 | 1 | |a Yamshchikov, Galina |e verfasserin |4 aut | |
| 700 | 1 | |a Koup, Richard A |e verfasserin |4 aut | |
| 700 | 1 | |a Graham, Barney S |e verfasserin |4 aut | |
| 700 | 1 | |a Millo, Corina M |e verfasserin |4 aut | |
| 700 | 1 | |a Ledgerwood, Julie E |e verfasserin |4 aut | |
| 700 | 0 | |a VRC 900 Study Team |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical nuclear medicine |d 1993 |g 42(2017), 5 vom: 20. Mai, Seite 329-334 |w (DE-627)NLM000990795 |x 1536-0229 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2017 |g number:5 |g day:20 |g month:05 |g pages:329-334 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/RLU.0000000000001603 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2017 |e 5 |b 20 |c 05 |h 329-334 | ||